 | Up a level |
Aringer, M; Burkhardt, H; Burmester, G R; Fischer-Betz, R; Fleck, M; Graninger, W; Hiepe, F; Jacobi, A M; Kötter, I; Lakomek, H J; Lorenz, H M; Manger, B; Schett, G; Schmidt, R E; Schneider, M; Schulze-Koops, H; Smolen, J S; Specker, C; Stoll, T; Strangfeld, A; ... (2012). Current state of evidence on 'off-label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria and Switzerland--a consensus report. Lupus, 21(4), pp. 386-401. London: Sage 10.1177/0961203311426569
Henes, M; Henes, J C; Neunhoeffer, E; Von Wolff, M; Schmalzing, M; Kötter, I; Lawrenz, B (2012). Fertility preservation methods in young women with systemic lupus erythematosus prior to cytotoxic therapy: experiences from the FertiPROTEKT network. Lupus, 21(9), pp. 953-8. London: Sage 10.1177/0961203312442753
Koenig, K F; Ribi, C; Radosavac, M; Zulewski, H; Trendelenburg, M; Huynh-Do, Uyen (2015). Prevalence of vascular disease in systemic lupus erythematosus compared with type-1 diabetes mellitus: a cross-sectional study of two cohorts. Lupus, 24(1), pp. 58-65. Sage 10.1177/0961203314550223
